Ignite Creation Date:
2024-05-11 @ 8:30 AM
Last Modification Date:
2024-10-26 @ 3:29 PM
Study NCT ID:
NCT06405321
Status:
RECRUITING
Last Update Posted:
2024-05-08
First Post:
2024-05-04
Brief Title:
Conversion or Neoadjuvant Therapy in Hepatocellular Carcinoma
Sponsor:
Guangxi Medical University
Organization:
Guangxi Medical University
Study Overview
Official Title:
Conversion or Neoadjuvant Therapy in Hepatocellular Carcinoma a Multicenter Retrospective Study in Guangxi China GUIDANCE
Status:
RECRUITING
Status Verified Date:
2024-09
Last Known Status:
None
Delayed Posting:
No
If Stopped, Why?:
Not Stopped
Has Expanded Access:
False
If Expanded Access, NCT#:
N/A
Has Expanded Access, NCT# Status:
N/A
Acronym:
None
Brief Summary:
This multicenter retrospective study which included patients with hepatocellular carcinoma HCC who received conversion or neoadjuvant therapy to explore the best treatment options and the best benefit group
Detailed Description:
More than 50 patients with initial hepatocellular carcinoma HCC are diagnosed as intermediate or advanced stage diease Transarterial chemoembolization and systemic therapy are main treatments for these patients With the rise of targeted drugs and immunotherapy more and more patients with advanced HCC have access to curative treatment thereby extending their overall survival time In clinical practice there are many combinations used to treat these patients However the safety and efficacy of conversion or neoadjuvant therapy in HCC patients remains controversial
The aim of this project is to establish a multicentre database from Guangxi province China to include as many HCC patients receiving conversion or neoadjuvant therapy as possible HCC patients who received conversion or neoadjuvant therapy as initial treatment including hepatic artery infusion chemotherapy HAIC transcatheter arterial chemoembolization TACE tyrosine kinase inhibitors TKIs immune checkpoint inhibitors ICIs or radiotherapy were retrospectively enrolled The purpose of this project is to explore the best beneficiaries of conversion or neoadjuvant therapy the best treatment strategy and the follow-up treatment options after successful conversion therapy The ultimate objective is to provide evidence for the necessity and feasibility of conversion or neoadjuvant therapy for patients with HCC
The data for this study were derived from the database of the regional registry platform entitled Guangxi Liver Cancer Clinical Study Alliance GUIDANCE sponsored by the Guangxi Anticancer Association Liver Cancer Committee All of the included patients were not previously reported and were not enrolled in those industry-sponsored clinical trials
The aim of this project is to establish a multicentre database from Guangxi province China to include as many HCC patients receiving conversion or neoadjuvant therapy as possible HCC patients who received conversion or neoadjuvant therapy as initial treatment including hepatic artery infusion chemotherapy HAIC transcatheter arterial chemoembolization TACE tyrosine kinase inhibitors TKIs immune checkpoint inhibitors ICIs or radiotherapy were retrospectively enrolled The purpose of this project is to explore the best beneficiaries of conversion or neoadjuvant therapy the best treatment strategy and the follow-up treatment options after successful conversion therapy The ultimate objective is to provide evidence for the necessity and feasibility of conversion or neoadjuvant therapy for patients with HCC
The data for this study were derived from the database of the regional registry platform entitled Guangxi Liver Cancer Clinical Study Alliance GUIDANCE sponsored by the Guangxi Anticancer Association Liver Cancer Committee All of the included patients were not previously reported and were not enrolled in those industry-sponsored clinical trials
Study Oversight
Has Oversight DMC:
None
Is a FDA Regulated Drug?:
False
Is a FDA Regulated Device?:
False
Is an Unapproved Device?:
None
Is a PPSD?:
None
Is a US Export?:
None
Is an FDA AA801 Violation?:
None